Biocon · NSE: BIOCON · BSE: 532523

Q2 FY23 results · Jul–Sep 2022

Biocon reported revenue from operations of ₹2,319.70 crore (up 26.0% from Q2 FY22) and net profit of ₹81.80 crore (down 48.8% from Q2 FY22) for Q2 FY23 (Jul–Sep 2022), on a consolidated basis.

Consolidated · ₹ crore
Item	Q2 FY23	Q2 FY22	YoY	Q1 FY23	QoQ
Revenue from operations	2,319.70	1,840.40	+26.0%	2,139.50	+8.4%
Other income	64.50	104.90	−38.5%	77.90	−17.2%
Total income	2,384.20	1,945.30	+22.6%	2,217.40	+7.5%
Profit before share of associates & JVs and tax	257.40	256.60	+0.3%	239.90	+7.3%
Share of profit/(loss) of associates & JVs	(28.30)	(50.60)		(43.00)
Net profit for the period	81.80	159.70	−48.8%	167.40	−51.1%
Attributable to shareholders of the company	46.90	138.30	−66.1%	144.40	−67.5%
EPS, basic (₹)	0.39	1.16	−66.4%	1.21	−67.8%
Net margin (%)	3.5	8.7		7.8

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q2 FY23	Q2 FY22	YoY	Q1 FY23	QoQ
Revenue from operations	489.50	364.80	+34.2%	441.70	+10.8%
Other income	98.90	40.50	+144.2%	48.60	+103.5%
Total income	588.40	405.30	+45.2%	490.30	+20.0%
Profit before tax	1,106.10	(9.30)	Turned profit	22.50	49x
Net profit for the period	987.50	(6.60)	Turned profit	14.90	66x
EPS, basic (₹)	8.28	(0.06)	Turned profit	0.12	69x
Net margin (%)	201.7	-1.8		3.4

Consolidated

Filed with BSE: 16 Nov 2022, 18:12 IST
Board meeting: 14 Nov 2022
Period: 01 Jul 2022 to 30 Sep 2022
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 16 Nov 2022, 18:12 IST
Board meeting: 14 Nov 2022
Period: 01 Jul 2022 to 30 Sep 2022
Review status: Unaudited
Source: XBRL filing on BSE